FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175655582> ?p ?o ?g. }

• W3175655582 endingPage "P" @default.
• W3175655582 startingPage "1087" @default.
• W3175655582 abstract "Therapy patterns were examined across various subgroups during the first year of LANDMARC, a 3-year prospective observational study (CTRI/2017/05/008452) that included patients with T2D on ≥2 antihyperglycemic medications. Of 6236 patients (mean baseline values - age: 52.1 years, T2D duration: 8.6 years and A1C: 8.05%) enrolled, 5654 completed 1-year follow-up visit. Therapeutic management was at the discretion of the treating physician. At the end of the first year, the proportion of patients taking insulin + OAD increased (baseline: 24%; 1-year: 30.7%); while, those taking only OADs decreased (baseline: 74.4%; 1-year: 67.3%). Biguanides and sulfonylureas were the most commonly used OAD classes, the highest increase in use was seen for DPP4 inhibitors (baseline: 48.9%; 1-year: 58.7%). Overall, at 1-year, glycemic parameters improved significantly (p≤0.001); HbA1c improved more in the insulin versus insulin naïve subgroup (p<0.0001) (Table); but no statistical difference was noted in those who received >3 versus ≤3 OADs. All glycemic parameters improved in those receiving basal or premix insulins. Overall, 1-year data indicate that timely initiation of insulin may play an important role in improving glycemic parameters.View largeDownload slideView largeDownload slide DisclosureH. Thacker: None. R. Ghosh: Employee; Self; Sanofi. S. Krishnan: Employee; Self; Sanofi. A. Nair: Employee; Self; Sanofi. S. Mohanasundaram: Employee; Self; Sanofi. S. K. Menon: Employee; Self; Sanofi. V. Salvi: Employee; Self; Sanofi. D. Chodankar: Employee; Self; Sanofi. C. Trivedi: None. S. Wangnoo: None. A. H. Zargar: None. A. K. Das: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Roche Pharma, Sanofi. N. Rais: None. S. Joshi: Advisory Panel; Self; Abbott, AstraZeneca, Biocon, Franco Indian, Glenmark, Lupin, Marico, Roche, Twinhealth, Zydus, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Sanofi, Serdia Pharmaceuticals (India) Pvt. Ltd. A. Mithal: Advisory Panel; Self; Eris Lifesciences Limited, Consultant; Self; Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals, Inc., USV Private Limited, Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Novo Nordisk, Sanofi. S. Kalra: Speaker’s Bureau; Self; Eli Lilly and Company, Novo Nordisk, Sanofi. A. Unnikrishnan: Advisory Panel; Self; Sanofi-Aventis, Other Relationship; Self; Novo Nordisk A/S, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes. K. Kumar: Advisory Panel; Self; Sanofi-Aventis. B. Sethi: None. S. Chowdhury: None.FundingSanofi" @default.
• W3175655582 created "2021-07-05" @default.
• W3175655582 creator A5000939264 @default.
• W3175655582 creator A5017520150 @default.
• W3175655582 creator A5023657826 @default.
• W3175655582 creator A5024786340 @default.
• W3175655582 creator A5033473100 @default.
• W3175655582 creator A5038060263 @default.
• W3175655582 creator A5038729212 @default.
• W3175655582 creator A5043986676 @default.
• W3175655582 creator A5046880976 @default.
• W3175655582 creator A5051792237 @default.
• W3175655582 creator A5058499466 @default.
• W3175655582 creator A5061688322 @default.
• W3175655582 creator A5066981564 @default.
• W3175655582 creator A5072408173 @default.
• W3175655582 creator A5073134238 @default.
• W3175655582 creator A5077236758 @default.
• W3175655582 creator A5078008450 @default.
• W3175655582 creator A5078049381 @default.
• W3175655582 creator A5078838356 @default.
• W3175655582 creator A5091531601 @default.
• W3175655582 date "2021-06-01" @default.
• W3175655582 modified "2023-10-04" @default.
• W3175655582 title "1087-P: Therapy Trends at One Year in the Longitudinal LANDMARC Study on Real-World Outcomes in Type 2 Diabetes Patients in India" @default.
• W3175655582 doi "https://doi.org/10.2337/db21-1087-p" @default.
• W3175655582 hasPublicationYear "2021" @default.
• W3175655582 type Work @default.
• W3175655582 sameAs 3175655582 @default.
• W3175655582 citedByCount "0" @default.
• W3175655582 crossrefType "journal-article" @default.
• W3175655582 hasAuthorship W3175655582A5000939264 @default.
• W3175655582 hasAuthorship W3175655582A5017520150 @default.
• W3175655582 hasAuthorship W3175655582A5023657826 @default.
• W3175655582 hasAuthorship W3175655582A5024786340 @default.
• W3175655582 hasAuthorship W3175655582A5033473100 @default.
• W3175655582 hasAuthorship W3175655582A5038060263 @default.
• W3175655582 hasAuthorship W3175655582A5038729212 @default.
• W3175655582 hasAuthorship W3175655582A5043986676 @default.
• W3175655582 hasAuthorship W3175655582A5046880976 @default.
• W3175655582 hasAuthorship W3175655582A5051792237 @default.
• W3175655582 hasAuthorship W3175655582A5058499466 @default.
• W3175655582 hasAuthorship W3175655582A5061688322 @default.
• W3175655582 hasAuthorship W3175655582A5066981564 @default.
• W3175655582 hasAuthorship W3175655582A5072408173 @default.
• W3175655582 hasAuthorship W3175655582A5073134238 @default.
• W3175655582 hasAuthorship W3175655582A5077236758 @default.
• W3175655582 hasAuthorship W3175655582A5078008450 @default.
• W3175655582 hasAuthorship W3175655582A5078049381 @default.
• W3175655582 hasAuthorship W3175655582A5078838356 @default.
• W3175655582 hasAuthorship W3175655582A5091531601 @default.
• W3175655582 hasConcept C126322002 @default.
• W3175655582 hasConcept C134018914 @default.
• W3175655582 hasConcept C142724271 @default.
• W3175655582 hasConcept C1862650 @default.
• W3175655582 hasConcept C23131810 @default.
• W3175655582 hasConcept C2777180221 @default.
• W3175655582 hasConcept C2777895361 @default.
• W3175655582 hasConcept C2779306644 @default.
• W3175655582 hasConcept C2780473172 @default.
• W3175655582 hasConcept C2909524832 @default.
• W3175655582 hasConcept C555293320 @default.
• W3175655582 hasConcept C71924100 @default.
• W3175655582 hasConceptScore W3175655582C126322002 @default.
• W3175655582 hasConceptScore W3175655582C134018914 @default.
• W3175655582 hasConceptScore W3175655582C142724271 @default.
• W3175655582 hasConceptScore W3175655582C1862650 @default.
• W3175655582 hasConceptScore W3175655582C23131810 @default.
• W3175655582 hasConceptScore W3175655582C2777180221 @default.
• W3175655582 hasConceptScore W3175655582C2777895361 @default.
• W3175655582 hasConceptScore W3175655582C2779306644 @default.
• W3175655582 hasConceptScore W3175655582C2780473172 @default.
• W3175655582 hasConceptScore W3175655582C2909524832 @default.
• W3175655582 hasConceptScore W3175655582C555293320 @default.
• W3175655582 hasConceptScore W3175655582C71924100 @default.
• W3175655582 hasIssue "Supplement 1" @default.
• W3175655582 hasLocation W31756555821 @default.
• W3175655582 hasOpenAccess W3175655582 @default.
• W3175655582 hasPrimaryLocation W31756555821 @default.
• W3175655582 hasRelatedWork W2015295066 @default.
• W3175655582 hasRelatedWork W2066909715 @default.
• W3175655582 hasRelatedWork W2263141914 @default.
• W3175655582 hasRelatedWork W2795301291 @default.
• W3175655582 hasRelatedWork W2887995587 @default.
• W3175655582 hasRelatedWork W3090938678 @default.
• W3175655582 hasRelatedWork W3143784901 @default.
• W3175655582 hasRelatedWork W4206946711 @default.
• W3175655582 hasRelatedWork W4248781434 @default.
• W3175655582 hasRelatedWork W76033548 @default.
• W3175655582 hasVolume "70" @default.
• W3175655582 isParatext "false" @default.
• W3175655582 isRetracted "false" @default.
• W3175655582 magId "3175655582" @default.
• W3175655582 workType "article" @default.